| Melanoma |
1 |
1 |
| Skin Cancer |
0 |
0.9 |
| Biologic Therapy |
0 |
0.63 |
| Cancer |
0 |
0.57 |
| Tumor |
0 |
0.49 |
| Toxicology |
0 |
0.42 |
| Insurance |
0 |
0.33 |
| Revenue and Practice Management |
0 |
0.99 |
| Clinical Research |
0 |
0.25 |
| Healthcare and Medical Technology |
0 |
0.98 |
| Adverse Effects |
0 |
0.16 |
| Chemotherapy |
0 |
0.16 |
| Cytokines |
0 |
0.16 |
| Immunotherapy |
0 |
0.16 |
| Interleukin-2 |
0 |
0.16 |
| Medical Oncology |
0 |
0.16 |
| Surgery |
0 |
0.16 |
| Tissue |
0 |
0.16 |
| Patient Safety |
0 |
0.14 |
| California |
0 |
0.08 |
| Clinical Guidelines |
0 |
0.08 |
| Food and Drug Administration (FDA) |
0 |
0.08 |
| Lymphocytes |
0 |
0.08 |
| Multidisciplinary Team |
0 |
0.08 |
| New York |
0 |
0.08 |
| Referral |
0 |
0.08 |